Protara Therapeutics, Inc. (TARA) shareholders
Close on Nov 17, 2026Market cap $137.10MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Janus Henderson Biotech Innovation Master Fund Ltd Joint filing with Janus Henderson Group PLC (6.60%) | 5,448,687 | 6.00% | 13G (passive) | Dec 31, 2024 |
| Janus Henderson Group PLC | 5,207,011 | 9.60% | 13G (passive) amendment | Mar 31, 2026 |
| JANUS HENDERSON GROUP Ltd. | 4,696,709 | 8.40% | 13G (passive) amendment | Jun 30, 2026 |
| Rajeev Shah Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more | 3,431,713 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| BlackRock, Inc. | 3,387,459 | 6.30% | 13G (passive) | Mar 31, 2026 |
| Millennium Management LLC Joint filing with Millennium Group Management LLC (5.70%), Israel A. Englander (5.70%) and 1 more | 3,201,936 | 5.70% | 13G (passive) amendment | Jul 1, 2026 |
| Velan Capital Investment Management LP Joint filing with Velan Capital Management LLC (5.90%), Adam Morgan (5.90%) and 3 more | 2,059,000 | 5.90% | 13G (passive) | Dec 10, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TARA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 4,696,709 | 7.95% | $17.92M | New | 0.01% |
| BlackRock, Inc. | 3,663,499 | 6.20% | $13.99M | +268,531 | 0.00% |
| Millennium Management LLC | 3,101,166 | 5.25% | $11.85M | +269,958 | 0.00% |
| Velan Capital Investment Management LP | 2,844,652 | 4.81% | $10.87M | +10,000 | 6.62% |
| Vanguard Capital Management LLC | 2,300,133 | 3.89% | $8.79M | +181,115 | 0.00% |
| Blackstone Inc. | 2,265,514 | 3.83% | $8.65M | – | 0.03% |
| Orbimed Advisors LLC | 2,220,000 | 3.76% | $8.48M | New | 0.16% |
| Sio Capital Management, LLC | 1,921,872 | 3.25% | $7.34M | −47,967 | 1.21% |
| Acorn Capital Advisors, LLC | 1,752,115 | 2.96% | $6.69M | – | 1.83% |
| Integral Health Asset Management, LLC | 1,500,000 | 2.54% | $5.73M | −250,000 | 0.23% |
| 5AM Venture Management, LLC | 1,369,782 | 2.32% | $5.23M | – | 1.82% |
| Geode Capital Management, LLC | 1,326,246 | 2.24% | $5.07M | +149,046 | 0.00% |
| Citadel Advisors LLC | 1,232,365 | 2.09% | $4.71M | +163,807 | 0.00% |
| State Street Corp | 1,068,295 | 1.81% | $4.08M | +63,153 | 0.00% |
| Qube Research & Technologies Ltd | 1,045,516 | 1.77% | $3.99M | +868,512 | 0.00% |
| Balyasny Asset Management L.P. | 1,026,691 | 1.74% | $3.92M | New | 0.00% |
| Baker Bros. Advisors LP | 971,614 | 1.64% | $3.71M | – | 0.02% |
| ADAR1 Capital Management, LLC | 940,512 | 1.59% | $3.59M | – | 0.16% |
| Bank Of America Corp /De/ | 882,179 | 1.49% | $3.37M | −43,739 | 0.00% |
| Marshall Wace, Llp | 701,021 | 1.19% | $2.68M | +650,290 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 120 | 46M | 78.1% | 26 / 51 | 28 / 17 | 13M | 7M |
| Q1 2026 | 114 | 46M | 77.1% | 31 / 48 | 23 / 21 | 15M | 7M |
| Q4 2025 | 105 | 40M | 67.4% | 32 / 45 | 16 / 7 | 15M | 1M |
| Q3 2025 | 81 | 26M | 44.4% | 14 / 25 | 25 / 8 | 2M | 5M |
| Q2 2025 | 76 | 30M | 50.3% | 25 / 27 | 13 / 8 | 7M | 6M |
| Q1 2025 | 59 | 29M | 48.7% | 8 / 24 | 12 / 9 | 5M | 6M |
| Q4 2024 | 60 | 30M | 50.2% | 30 / 15 | 10 / 5 | 21M | 2M |
| Q3 2024 | 35 | 10M | 17.7% | 6 / 13 | 7 / 7 | 2M | 1M |
| Q2 2024 | 38 | 10M | 17.7% | 11 / 14 | 7 / 7 | 6M | 1M |
| Q1 2024 | 34 | 5M | 7.7% | 7 / 8 | 9 / 3 | 0M | 0M |
| Q4 2023 | 30 | 4M | 7.4% | 2 / 7 | 6 / 3 | 0M | 1M |
| Q3 2023 | 31 | 5M | 8.7% | 4 / 3 | 9 / 2 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
109 funds held TARA in Q2 2026, 66% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TARA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,657,879 | 2.81% | $6.33M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,364,271 | 2.31% | $5.21M | 0.01% | Jun 30, 2026 |
| Columbia Small Cap Value Discovery Fund | 758,070 | 1.28% | $2.97M | 0.12% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 586,965 | 0.99% | $2.24M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 569,271 | 0.96% | $2.23M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 475,364 | 0.80% | $1.82M | 0.01% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 264,329 | 0.45% | $1.23M | 0.01% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 241,686 | 0.41% | $1.12M | 0.00% | May 31, 2026 |
| U.S. Small Cap Portfolio | 182,472 | 0.31% | $715.29K | 0.00% | Jul 31, 2026 |
| iShares Micro-Cap ETF | 175,831 | 0.30% | $671.67K | 0.04% | Jun 30, 2026 |
| Vanguard U.S. Momentum Factor ETF | 141,979 | 0.24% | $660.20K | 0.04% | May 31, 2026 |
| U.S. Micro Cap Portfolio | 131,860 | 0.22% | $516.89K | 0.01% | Jul 31, 2026 |
| Dimensional U.S. Small Cap ETF | 125,321 | 0.21% | $491.26K | 0.00% | Jul 31, 2026 |
| Schwab Small-Cap Index Fund | 122,956 | 0.21% | $481.99K | 0.01% | Jul 31, 2026 |
| Small Cap Value Fund | 117,674 | 0.20% | $449.51K | 0.07% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jesse Shefferman | CEO and President, Director | 1,007,832 | 1.71% | Jul 1, 2026 |
| William Conkling | Chief Commercial Officer | 69,992 | 0.12% | Jun 3, 2026 |
| Jacqueline Zummo | Chief R&D Officer | 94,827 | 0.16% | Apr 9, 2026 |
| Hannah Fry | VP, Controller | 42,723 | 0.07% | Jan 27, 2026 |
| Patrick Fabbio | Chief Financial Officer | 64,115 | 0.11% | Jan 27, 2026 |
| Leonardo Viana Nicacio | Chief Medical Officer | 78,181 | 0.13% | Jan 21, 2026 |
| Cynthia Smith | Director | – | – | Jun 16, 2026 |
| Michael Edward Solomon | Director | 26,500 | 0.04% | Jun 16, 2026 |
| Gregory Sargen | Director | 31,000 | 0.05% | Jun 16, 2026 |
| Roger Garceau | Director | 33,000 | 0.06% | Jun 16, 2026 |
| Jane Huang | Director | – | – | Jun 16, 2026 |
| Luke M. Beshar | Director | 198,000 | 0.34% | Jun 16, 2026 |
| Barry P. Flannelly | Director | – | – | Jun 16, 2026 |
| Richard S. Levy | Director | 51,000 | 0.09% | Jun 16, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jesse Shefferman CEO and President, Director | Jun 30, 2026 | Gift | −14,000 | – | – | 707,832 |
| Jesse Shefferman CEO and President, Director | Jun 30, 2026 | Gift | −7,000 | – | – | 700,832 |
| Jesse Shefferman CEO and President, Director | Jun 30, 2026 | Gift | −5,000 | – | – | 691,832 |
| Jesse Shefferman CEO and President, Director | Jun 30, 2026 | Gift | −4,000 | – | – | 696,832 |
| Jesse Shefferman CEO and President, Director | Jun 29, 2026 | Sale | −215,687 | $4.09 | $882.16K | 721,832 |
| Jesse Shefferman CEO and President, Director | Jun 29, 2026 | Option exercise | +215,687 | $1.91 | $411.96K | 937,519 |
| William Conkling Chief Commercial Officer | Jun 2, 2026 | Tax withholding | −6,008 | $4.34 | $26.07K | 69,992 |
| Jacqueline Zummo Chief R&D Officer | Apr 8, 2026 | Sale(10b5-1 plan) | −1,134 | $5.40 | $6.12K | 94,827 |
| Jacqueline Zummo Chief R&D Officer | Apr 1, 2026 | Sale(10b5-1 plan) | −22,598 | $5.26 | $118.87K | 95,961 |
| Jesse Shefferman CEO and President, Director | Jan 26, 2026 | Tax withholding | −8,732 | $6.67 | $58.24K | 1,021,832 |
| Jacqueline Zummo Chf Scientific Operations Off | Jan 26, 2026 | Tax withholding | −3,724 | $6.67 | $24.84K | 118,559 |
| Patrick Fabbio Chief Financial Officer | Jan 26, 2026 | Tax withholding | −3,261 | $6.67 | $21.75K | 64,115 |
| Hannah Fry VP, Controller | Jan 26, 2026 | Tax withholding | −1,457 | $6.67 | $9.72K | 42,723 |
| Jesse Shefferman CEO and President, Director | Jan 20, 2026 | Tax withholding | −16,322 | $5.60 | $91.40K | 1,030,564 |
| Hannah Fry VP, Controller | Jan 20, 2026 | Tax withholding | −2,132 | $5.60 | $11.94K | 44,180 |
| Patrick Fabbio Chief Financial Officer | Jan 20, 2026 | Tax withholding | −3,063 | $5.60 | $17.15K | 67,376 |
| Jacqueline Zummo Chf Scientific Operations Off | Jan 20, 2026 | Tax withholding | −6,578 | $5.60 | $36.84K | 122,283 |
| Hannah Fry VP, Controller | Jan 16, 2026 | Award | +9,500 | – | – | 46,312 |
| Leonardo Viana Nicacio Chief Medical Officer | Jan 16, 2026 | Award | +26,000 | – | – | 78,181 |
| William Conkling Chief Commercial Officer | Jan 16, 2026 | Award | +26,000 | – | – | 76,000 |
| Jesse Shefferman CEO and President, Director | Jan 16, 2026 | Award | +87,000 | – | – | 1,046,886 |
| Patrick Fabbio Chief Financial Officer | Jan 16, 2026 | Award | +28,000 | – | – | 70,439 |
| Jacqueline Zummo Chf Scientific Operations Off | Jan 16, 2026 | Award | +30,000 | – | – | 128,861 |
| Jesse Shefferman CEO and President, Director | Jun 27, 2025 | Gift | −10,200 | – | – | 963,253 |
| Jesse Shefferman CEO and President, Director | Jun 27, 2025 | Gift | −3,367 | – | – | 959,886 |
| Jesse Shefferman CEO and President, Director | Jun 26, 2025 | Gift | −3,400 | – | – | 973,453 |
| Jesse Shefferman CEO and President, Director | Jun 26, 2025 | Gift | −1,700 | – | – | 976,853 |
| Jesse Shefferman CEO and President, Director | Jun 24, 2025 | Gift | −300,000 | – | – | 659,886 |
| William Conkling Chief Commercial Officer | Jun 2, 2025 | Award | +50,000 | – | – | 50,000 |
| Richard S. Levy Director | May 14, 2025 | Buy | +20,000 | $3.19 | $63.80K | 51,000 |
| Richard S. Levy Director | May 14, 2025 | Buy | +20,000 | $3.19 | $63.80K | 51,000 |
| Leonardo Viana Nicacio Chief Medical Officer | Apr 15, 2025 | Award | +50,000 | – | – | 52,181 |
| Jacqueline Zummo Chf Scientific Operations Off | Mar 26, 2025 | Sale(10b5-1 plan) | −21,224 | $4.53 | $96.14K | 98,861 |
| Patrick Fabbio Chief Financial Officer | Jan 24, 2025 | Award | +23,500 | – | – | 45,500 |
| Jacqueline Zummo Chf Scientific Operations Off | Jan 24, 2025 | Award | +24,500 | – | – | 126,639 |
| Jesse Shefferman CEO and President, Director | Jan 24, 2025 | Award | +65,000 | – | – | 994,022 |
| Hannah Fry VP, Controller | Jan 24, 2025 | Award | +9,500 | – | – | 38,942 |
| Jesse Shefferman CEO and President, Director | Jan 21, 2025 | Tax withholding | −15,469 | $4.76 | $73.63K | 913,553 |
| Patrick Fabbio Chief Financial Officer | Jan 21, 2025 | Tax withholding | −3,061 | $4.76 | $14.57K | 18,939 |
| Jacqueline Zummo Chf Scientific Operations Off | Jan 21, 2025 | Tax withholding | −6,554 | $4.76 | $31.20K | 95,585 |
| Hannah Fry VP, Controller | Jan 21, 2025 | Tax withholding | −2,130 | $4.76 | $10.14K | 27,312 |
| Hannah Fry VP, Controller | Jan 3, 2025 | Tax withholding | −394 | $6.14 | $2.42K | 29,442 |
| Jesse Shefferman CEO and President, Director | Jan 3, 2025 | Tax withholding | −6,479 | $6.14 | $39.78K | 929,022 |
| Jacqueline Zummo Chf Scientific Operations Off | Jan 3, 2025 | Tax withholding | −2,157 | $6.14 | $13.24K | 102,139 |
| Management Inc. Opaleye 10% owner | Sep 12, 2024 | Sale | −119,801 | $1.71 | $204.86K | 1,944,134 |
| Management Inc. Opaleye 10% owner | Sep 12, 2024 | Sale | −6,500 | $1.71 | $11.12K | 45,000 |
| Management Inc. Opaleye 10% owner | Sep 11, 2024 | Sale | −1,600 | $1.71 | $2.74K | 51,500 |
| Management Inc. Opaleye 10% owner | Sep 11, 2024 | Sale | −31,000 | $1.71 | $53.01K | 2,063,935 |
| Management Inc. Opaleye 10% owner | Sep 10, 2024 | Sale | −1,500 | $1.77 | $2.66K | 53,100 |
| Management Inc. Opaleye 10% owner | Sep 10, 2024 | Sale | −24,000 | $1.77 | $42.48K | 2,094,935 |
| Management Inc. Opaleye 10% owner | Sep 9, 2024 | Sale | −1,900 | $1.89 | $3.59K | 54,600 |
| Management Inc. Opaleye 10% owner | Sep 9, 2024 | Sale | −34,592 | $1.89 | $65.38K | 2,118,935 |
| Jesse Shefferman CEO and President, Director | Aug 28, 2024 | Gift | −3,300 | – | – | 935,501 |
| Jesse Shefferman CEO and President, Director | Aug 28, 2024 | Gift | −5,263 | – | – | 938,801 |
| Management Inc. Opaleye 10% owner | Jul 16, 2024 | Sale | −3,500 | $2.44 | $8.54K | 56,500 |
| Management Inc. Opaleye 10% owner | Jul 16, 2024 | Sale | −7,896 | $2.44 | $19.27K | 2,153,527 |
| Management Inc. Opaleye 10% owner | Jul 11, 2024 | Sale | −15,000 | $2.40 | $36.00K | 60,000 |
| Management Inc. Opaleye 10% owner | Jul 11, 2024 | Sale | −32,993 | $2.40 | $79.18K | 2,161,423 |
| Management Inc. Opaleye 10% owner | Jul 10, 2024 | Sale | −5,000 | $2.31 | $11.55K | 75,000 |
| Management Inc. Opaleye 10% owner | Jul 10, 2024 | Sale | −13,061 | $2.31 | $30.17K | 2,194,416 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Protara Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 21 shares on Aug 31, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jesse Shefferman Officer, Director | Jun 29, 2026 | 215,687 | $882.01K | Jun 29, 2026 | Stock Option Exercise |
| Baker Brothers Life Sciences, L.P. Former Affiliate | Apr 23, 2026 | 300,176 | $1.61M | Apr 23, 2026 | See Remark 2 |
| 667, L.P. Former Affiliate | Apr 23, 2026 | 24,802 | $132.69K | Apr 23, 2026 | See Remark 2 |
| Jacqueline Zummo Officer | Apr 1, 2026 | 23,732 | $124.83K | Apr 1, 2026 | RSU GRANTS ACQUIRED BETWEEN: 1/10/21 to 1/19/25 |
| Baker Brothers Life Sciences, L.P. Former Affiliate | Mar 6, 2026 | 461,723 | $2.70M | Mar 6, 2026 | See Remark 2 |
| 667, L.P. Former Affiliate | Mar 6, 2026 | 38,277 | $223.92K | Mar 6, 2026 | See Remark 2 |
| Baker Brothers Life Sciences, L.P. Former Affiliate | Mar 4, 2026 | 424,125 | $2.65M | Mar 4, 2026 | See Remark 2 |
| 667, L.P. Former Affiliate | Mar 4, 2026 | 35,173 | $220.15K | Mar 4, 2026 | See Remark 2 |
| Baker Brothers Life Sciences, L.P. Former Affiliate | Feb 25, 2026 | 947,479 | $5.50M | Feb 25, 2026 | See Remark 2 |
| 667, L.P. Former Affiliate | Feb 25, 2026 | 78,716 | $457.05K | Feb 25, 2026 | See Remark 2 |
| Baker Brothers Life Sciences, L.P. Former Affiliate | Feb 24, 2026 | 322,039 | $1.94M | Feb 24, 2026 | See Remark 2 |
| 667, L.P. Former Affiliate | Feb 24, 2026 | 26,755 | $161.58K | Feb 24, 2026 | See Remark 2 |
| Jacqueline Zummo Officer | Mar 26, 2025 | 21,224 | $96.57K | Mar 26, 2025 | RSU GRANTS ACQUIRED BETWEEN: 1/3/23 - 1/19/24 |
See a number that looks wrong?